Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer patients treated with abiraterone
The Prostate2017Vol. 77(12), pp. 1233–1241
Citations Over TimeTop 10% of 2017 papers
Liancheng Fan, Xiao Wang, Chenfei Chi, Yanqing Wang, Wen Cai, Xiaoguang Shao, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Rui Wang, Lixin Zhou, Baijun Dong, Wei Xue
Abstract
Independent of PSA level variation, PNI level elevation during the first month of AA treatment and high baseline PNI level were significantly correlated with initial response to AA treatment. In addition, low pretreatment PNI level is a negative independent prognosticator of survival outcomes in mCRPC treated with AA and also increases the accuracy of established prognostic model.
Related Papers
- → Abiraterone and its place in the treatment of metastatic CRPC(2012)12 cited
- → Abiraterone acetate to treat metastatic castration-resistantprostate cancer in combination with prednisone(2019)3 cited
- Urologists positive about abiraterone integration(2017)
- → Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302)(2018)
- → Abiraterone acetate promising in the treatment of prostate cancer(2007)